Ratios Reveal: Breaking Down Novartis AG ADR (NVS)’s Financial Health

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

Novartis AG ADR (NYSE: NVS) closed the day trading at $102.10 up 1.89% from the previous closing price of $100.21. In other words, the price has increased by $1.89 from its previous closing price. On the day, 1.84 million shares were traded. NVS stock price reached its highest trading level at $102.14 during the session, while it also had its lowest trading level at $101.04.

Ratios:

For a better understanding of NVS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.71. For the most recent quarter (mrq), Quick Ratio is recorded 0.71 and its Current Ratio is at 0.90. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.47.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on February 23, 2024, initiated with a Market Perform rating and assigned the stock a target price of $114.

On January 23, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $114.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVS now has a Market Capitalization of 208325853184 and an Enterprise Value of 225987493888. As of this moment, Novartis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.86, and their Forward P/E ratio for the next fiscal year is 12.89. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.11 while its Price-to-Book (P/B) ratio in mrq is 5.25. Its current Enterprise Value per Revenue stands at 4.734 whereas that against EBITDA is 11.929.

Stock Price History:

The Beta on a monthly basis for NVS is 0.58, which has changed by -0.009891391 over the last 52 weeks, in comparison to a change of 0.26265144 over the same period for the S&P500. Over the past 52 weeks, NVS has reached a high of $108.78, while it has fallen to a 52-week low of $88.86. The 50-Day Moving Average of the stock is 5.07%, while the 200-Day Moving Average is calculated to be 3.94%.

Shares Statistics:

Over the past 3-months, NVS traded about 1.61M shares per day on average, while over the past 10 days, NVS traded about 1425270 shares per day. A total of 2.04B shares are outstanding, with a floating share count of 1.96B. Insiders hold about 0.00% of the company’s shares, while institutions hold 7.32% stake in the company. Shares short for NVS as of 1714435200 were 4217578 with a Short Ratio of 2.63, compared to 1711584000 on 4208167.

Dividends & Splits

NVS’s forward annual dividend rate is 3.74, up from 3.919 a year ago. Against a Trailing Annual Dividend Yield of 0.039107874The stock’s 5-year Average Dividend Yield is 3.59. The current Payout Ratio is 44.73% for NVS, which recently paid a dividend on 2024-03-07 with an ex-dividend date of 1709769600. Stock splits for the company last occurred on 2019-04-09 when the company split stock in a 1116:1000 ratio.

Earnings Estimates

The dynamic stock of Novartis AG ADR (NVS) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.On average, analysts expect EPS of $1.84 for the current quarter, with a high estimate of $1.94 and a low estimate of $1.78, while EPS last year was $1.83. The consensus estimate for the next quarter is $1.88, with high estimates of $1.97 and low estimates of $1.81.

Analysts are recommending an EPS of between $8.41 and $6.74 for the fiscal current year, implying an average EPS of $7.27. EPS for the following year is $8.03, with 17.0 analysts recommending between $9.38 and $7.41.

Revenue Estimates

4 analysts predict $12.13B in revenue for the current quarter. It ranges from a high estimate of $12.38B to a low estimate of $11.82B. As of the current estimate, Novartis AG ADR’s year-ago sales were $13.62BFor the next quarter, 4 analysts are estimating revenue of $12.23B. There is a high estimate of $12.43B for the next quarter, whereas the lowest estimate is $11.96B.

A total of 16 analysts have provided revenue estimates for NVS’s current fiscal year. The highest revenue estimate was $50.41B, while the lowest revenue estimate was $47.28B, resulting in an average revenue estimate of $49.07B. In the same quarter a year ago, actual revenue was $45.44BBased on 16 analysts’ estimates, the company’s revenue will be $51.21B in the next fiscal year. The high estimate is $53.88B and the low estimate is $47.62B.

Most Popular

[the_ad id="945"]